Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Howard

Showing results (401-410 of 429) with videos related to

Pageof 43
Sort By:
Neurology|December 6, 2008
Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review) [RETIRED]. Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and RehabilitationJ D England, G S Gronseth, G Franklin, et al.
American Journal of Human Genetics|January 21, 2014
Mutations in PGAP3 impair GPI-anchor maturation, causing a subtype of hyperphosphatasia with mental retardationMalcolm F Howard, Yoshiko Murakami, Alistair T Pagnamenta, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|July 25, 2009
Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and RehabilitationJ D England, G S Gronseth, G Franklin, et al.
Infection and Immunity|November 30, 2016
The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking VaccinesDiego A Espinosa, Joel Vega-Rodriguez, Yevel Flores-Garcia, et al.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 6, 2012
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategiesJoe N Kornegay, Janet R Bogan, Daniel J Bogan, et al.
NPJ Vaccines|December 22, 2017
A defined subunit vaccine that protects against vector-borne visceral leishmaniasisMalcolm S Duthie, Lais Pereira, Michelle Favila, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Human Molecular Genetics|August 22, 2015
Mutations in PIGY: expanding the phenotype of inherited glycosylphosphatidylinositol deficienciesBiljana Ilkovski, Alistair T Pagnamenta, Gina L O'Grady, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Pageof 43

Showing results (401-410 of 429) with videos related to

Sort By:
Pageof 43
Neurology|December 6, 2008
Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review) [RETIRED]. Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and RehabilitationJ D England, G S Gronseth, G Franklin, et al.
American Journal of Human Genetics|January 21, 2014
Mutations in PGAP3 impair GPI-anchor maturation, causing a subtype of hyperphosphatasia with mental retardationMalcolm F Howard, Yoshiko Murakami, Alistair T Pagnamenta, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|July 25, 2009
Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and RehabilitationJ D England, G S Gronseth, G Franklin, et al.
Infection and Immunity|November 30, 2016
The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking VaccinesDiego A Espinosa, Joel Vega-Rodriguez, Yevel Flores-Garcia, et al.
Neurology|August 13, 2017
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective reviewMichael K Hehir, Lisa D Hobson-Webb, Michael Benatar, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 6, 2012
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategiesJoe N Kornegay, Janet R Bogan, Daniel J Bogan, et al.
NPJ Vaccines|December 22, 2017
A defined subunit vaccine that protects against vector-borne visceral leishmaniasisMalcolm S Duthie, Lais Pereira, Michelle Favila, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Human Molecular Genetics|August 22, 2015
Mutations in PIGY: expanding the phenotype of inherited glycosylphosphatidylinositol deficienciesBiljana Ilkovski, Alistair T Pagnamenta, Gina L O'Grady, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Pageof 43